Drugs / IS-001
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03006237 | Dec 2016 → Dec 2017 | — | Intuitive Surgical | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05769257 | Jun 2023 → Mar 2024 | ureteral disorder | Intuitive Surgical | Completed | No outcome recorded |
| Phase 2 | NCT03937505 | May 2019 → Jul 2021 | ureteral disorder | Intuitive Surgical | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05954767 | Jan 2024 → Jan 2025 | ureteral disorder | Intuitive Surgical | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IS-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05769257 ↗ |
| Modality | Diagnostic / imaging agent | “The fluorescent imaging agent IS-001 was determined to be well tolerated in all subjects and has the potential to provide ureter visualization throughout minimally invasive...” PMID 31215195 ↗ Jun 2019 |
| Route | Intravenous | “40 mg IV IS-001 drug administered during surgery” NCT03006237 ↗ |